PT1272897E - Antagonistas de receptores a2a para a adenosina para o tratamento e prevenção da fibrose hepática, cirrose e fígado gordo - Google Patents

Antagonistas de receptores a2a para a adenosina para o tratamento e prevenção da fibrose hepática, cirrose e fígado gordo Download PDF

Info

Publication number
PT1272897E
PT1272897E PT01910529T PT01910529T PT1272897E PT 1272897 E PT1272897 E PT 1272897E PT 01910529 T PT01910529 T PT 01910529T PT 01910529 T PT01910529 T PT 01910529T PT 1272897 E PT1272897 E PT 1272897E
Authority
PT
Portugal
Prior art keywords
adenosine
fatty liver
cirrhosis
treating
receptor antagonists
Prior art date
Application number
PT01910529T
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce N Cronstein
Edwin Chan
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of PT1272897E publication Critical patent/PT1272897E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT01910529T 2000-02-10 2001-02-12 Antagonistas de receptores a2a para a adenosina para o tratamento e prevenção da fibrose hepática, cirrose e fígado gordo PT1272897E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18154600P 2000-02-10 2000-02-10

Publications (1)

Publication Number Publication Date
PT1272897E true PT1272897E (pt) 2008-08-18

Family

ID=22664744

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01910529T PT1272897E (pt) 2000-02-10 2001-02-12 Antagonistas de receptores a2a para a adenosina para o tratamento e prevenção da fibrose hepática, cirrose e fígado gordo

Country Status (11)

Country Link
US (1) US6555545B2 (enExample)
EP (1) EP1272897B1 (enExample)
JP (1) JP2004502640A (enExample)
AT (1) ATE394104T1 (enExample)
AU (2) AU3812401A (enExample)
CA (1) CA2398908C (enExample)
DE (1) DE60133887D1 (enExample)
DK (1) DK1272897T3 (enExample)
ES (1) ES2307593T3 (enExample)
PT (1) PT1272897E (enExample)
WO (1) WO2001058241A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6196459B1 (en) * 1998-05-11 2001-03-06 Ubiq Incorporated Smart card personalization in a multistation environment
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
ITRM20070088A1 (it) * 2007-02-19 2008-08-20 Francesco Fringuelli Composti derivati della colchicina, procedimento per la loro preparazione e usi in campo medico.
EA201000201A1 (ru) * 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
JP5302900B2 (ja) * 2008-01-31 2013-10-02 アステラス製薬株式会社 脂肪性肝疾患の治療用医薬組成物
WO2010040003A2 (en) * 2008-10-01 2010-04-08 The Scripps Research Institute Human a2a adenosine receptor crystals and uses thereof
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
SI2408775T1 (sl) * 2009-03-20 2015-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
US8809525B2 (en) 2010-02-05 2014-08-19 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
JP2020525472A (ja) 2017-06-30 2020-08-27 ライブ・セラピューティクス・スプウカ・アクツィーナＲｙｖｕ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓ．Ａ． アデノシンａ２ａ受容体のイミダゾ［１，２−ａ］ピラジン調節剤
US20200316077A1 (en) 2017-12-19 2020-10-08 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
JP7361697B2 (ja) 2018-01-04 2023-10-16 インペティス・バイオサイエンシーズ・リミテッド 三環性化合物、組成物及びその医薬品用途
WO2020128036A1 (en) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
WO2025018901A1 (en) 2023-07-17 2025-01-23 Ryvu Therapeutics S.A. Modulators of the adenosine a2a and a2b receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705658A (en) 1986-04-07 1987-11-10 Capsule Technology International, Ltd. Method for drying gelatin in the manufacture of hard shell gelatin capsules
US5063233A (en) 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5036381A (en) 1990-06-15 1991-07-30 Motorola, Inc. Multiple electronic devices within a single carrier structure
GB2264948B (en) 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
US5426101A (en) 1992-09-30 1995-06-20 Merrell Dow Pharmaceuticals Inc. 2-substituted adenosines with A-2 receptor affinity
WO1994023723A1 (en) 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5859019A (en) 1997-03-07 1999-01-12 Trustees Of The University Of Pennsylvania Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
EP1272897B1 (en) 2008-05-07
WO2001058241A9 (en) 2002-10-17
AU2001238124B2 (en) 2006-05-25
ES2307593T3 (es) 2008-12-01
DE60133887D1 (de) 2008-06-19
CA2398908A1 (en) 2001-08-16
CA2398908C (en) 2009-12-15
EP1272897A2 (en) 2003-01-08
US20020002145A1 (en) 2002-01-03
DK1272897T3 (da) 2008-09-15
JP2004502640A (ja) 2004-01-29
ATE394104T1 (de) 2008-05-15
WO2001058241A2 (en) 2001-08-16
AU3812401A (en) 2001-08-20
US6555545B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
AU3812401A (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
WO2005027895A3 (en) Thyroid hormone analogs and methods of use in angiogenesis
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
MY129445A (en) Compositions for treating inflammatory response
NZ511131A (en) Estrogen agonists/antagonists and cGMP elevators for treating female sexual dysfunction
EP1097709A3 (en) Use of corticotropin releasing factor antagonists for treating syndrome X
CO5060502A1 (es) Mezclas insecticidas sinergicas que comprenden espinosad y un cloronicotinilo
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
MXPA04005003A (es) Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo.
DE69232287D1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
MXPA02003150A (es) Uso de ribosa para prevenir calambres e inflamacion en musculos.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
JP2004502640A5 (enExample)
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
ZA200005413B (en) Cholesterol sulfate compositions for enhancement of stratum corneum function.
NZ506529A (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
IL126175A0 (en) Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same
GB9822566D0 (en) Cutlery to assist feeding and improve co-ordination
EP1613369A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
HUP0204516A3 (en) Synergistic fungicidal composition and its use
AU2003224808A8 (en) Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
EP1084706A3 (en) Use of simethicone to treat ulcerative colitis
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin